abolished B-T-cell cross talk as a result of B-cell depletion in lymphoma patients treated with rituximab. Significantly more pronounced T-cell expansions/imbalances were observed in patients with LON who also exhibited extensive hypoplasia of the granulocytic series with concomitant dyshematopoiesis of moderate-to-severe degree affecting all myeloid series. Therefore, our study demonstrates a remarkable analogy between rituximab-associated LON and neutropenia associated with T-LGL leukemia, which is characterized by BM dyshematopoiesis and/or maturation arrest of the granulocytic series mimicking primary MDS. Of note, BM abnormalities were also evident in rituximab-treated patients without LON, who, in stark contrast to LON cases, were characterized by hyperplasia of all myeloid series albeit again associated with varying degrees of dyshematopoiesis. Taken together, our findings indicate that rituximabassociated LON is multifactorial and may perhaps represent the end of a spectrum of immunohematological sequellae in the context of T-LGL-mediated autoimmune myelopathy/myelodysplasia.
waf1 and activation of caspase 3 in bone marrow mononuclear cells, although no responses were observed by classical criteria. 6 Taken together, combination of MS-275 and AD6244 may be useful for treatment of individuals with AML. Further studies are required to verify the molecular mechanisms by which blockade of MEK/ERK signaling affects chromatin remodeling. waf1 promoter was analyzed by chromatin immunoprecipitation assay. HL60 and NB4 cells were cultured in the presence of either MS-275 (0.5 mM) and/or AZD6244 (0.25 mM). After 6 h, cells were harvested and subjected to chromatin immunoprecipitation assay. Anti-acetylated histone H3 antibody or rabbit immunoglobulin G (IgG) was used to immunoprecipitate soluble chromatin from these cells. The recovered DNAs were subjected to PCR using primers for p21 waf1 promoter. The result is representative of two additional experiments performed independently. 
